Clinical Trials Logo

Clinical Trial Summary

To compare the efficacy and safety of NPB-01 in patients with autoimmune encephalitis refractory to steroid pulse therapy using steroid pulse therapy as a control.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT05177939
Study type Interventional
Source Nihon Pharmaceutical Co., Ltd
Contact Mamoru Ota
Phone 03-5148-7574
Email [email protected]
Status Not yet recruiting
Phase Phase 3
Start date February 1, 2022
Completion date October 31, 2024

See also
  Status Clinical Trial Phase
Not yet recruiting NCT04372615 - The ExTINGUISH Trial of Inebilizumab in NMDAR Encephalitis Phase 2
Active, not recruiting NCT04708626 - Cumulative Incidence of Autoimmune Encephalitides and Paraneoplastic Neurological Syndromes in Sweden
Not yet recruiting NCT04106596 - HLA Analysis in Autoimmune Encephalitis and Related Disorders
Completed NCT04175522 - Safety and Efficacy of IGIV 10% in Patients With Autoimmune Encephalitis: Phase 2
Recruiting NCT03194815 - IVIG and Rituximab in Antibody-associated Psychosis - SINAPPS2 Phase 2
Not yet recruiting NCT03957616 - Incidence of Paraneoplastic Neurological Syndromes and Autoimmune Encephalitis
Completed NCT02905136 - Mechanisms of Auto-immune Encephalitis
Recruiting NCT03993262 - Trial to Evaluate Efficacy and Safety of Bortezomib in Patients With Severe Autoimmune Encephalitis Phase 2
Recruiting NCT03872284 - Neuro-ophthalmology and Autoimmune Encephalitis (NODE)
Terminated NCT03835728 - Efficacy of Ocrelizumab in Autoimmune Encephalitis Phase 2
Recruiting NCT04823728 - HLA Analysis in Autoimmune Encephalitis and Related Disorders: Part II
Recruiting NCT03542279 - Immunotherapy in Autoimmune Encephalitis N/A
Withdrawn NCT03004209 - Effect of Erythropoietin in Refractory Autoimmune Encephalitis Patients Phase 4
Completed NCT03530462 - To Explore Cognitive Neural Mechanism of Autoimmune Encephalitis by Using Neuropsychological Tests and Multi-modal MRI
Recruiting NCT04339127 - Autoimmune Encephalitis With Anti-NMDA Receptor Antibodies Following Herpetic Encephalitis